Ergocalciferol
drugOn this page
Also known as CalciferolDeltalinDrisdolEciferol d2Ergo-d2Ergocalciferol component of vitapedErgocalciferolumErgoral d2ErgoroneNSC-62792OstelinSterogylSterogyl 15hSterogyl-15Uvesterol dViosterolVitamin dVitamin d (ergocalciferol)Vitamin d nos
Summary
Ergocalciferol (CHEMBL1536) is an approved small-molecule bone density conservation agent (ATC A11CC01); indicated across 78 conditions including hypoparathyroidism and hypophosphatemic rickets.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A11CC01
- Indications: 78 conditions
- Clinical trials: 617
- Chemistry: 396.6 Da · C28H44O
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1536 |
| Name | Ergocalciferol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5280793 |
| ChEBI | CHEBI:28934 |
| ATC | A11CC01 |
| Molecular formula | C28H44O |
| Molecular weight | 396.6 |
| InChIKey | MECHNRXZTMCUDQ-RKHKHRCZSA-N |
SMILES: C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
IUPAC name: (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
ChEBI definition: A vitamin D supplement and has been isolated from alfalfa.
Pharmacological roles (ChEBI): nutraceutical, bone density conservation agent, rodenticide.
Other ChEBI roles (chemical / environmental): plant metabolite.
Also known as: Calciferol, Deltalin, Drisdol, Eciferol d2, Ergo-d2, Ergocalciferol, Ergocalciferol component of vitaped, Ergocalciferolum, Ergoral d2, Ergorone, NSC-62792, Ostelin
Patent coverage: 13,616 distinct patent families (35,524 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Beta-lactamase, Estrogen receptor, Prostaglandin G/H synthase 1, Alpha-1A adrenergic receptor, HSP60/HSP10, Thiosulfate sulfurtransferase, Bile salt export pump.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P00811 | 5.25 | Potency | 5623 | nM | CHEMBL_ACT_4673435 |
| ESR1 | 5.08 | AC50 | 8300 | nM | CHEMBL_ACT_25139047 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
78 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hypoparathyroidism | 4 | MONDO:0001220 | EFO:0009451 |
| hypophosphatemic rickets | 4 | MONDO:0024300 | MONDO:0024300 |
| chronic kidney disease | 3 | MONDO:0005300 | EFO:0003884 |
| breast neoplasm | 3 | MONDO:0021100 | EFO:0003869 |
| hip fracture | 3 | MONDO:0005327 | EFO:0003964 |
| vitamin D deficiency | 3 | MONDO:0100471 | EFO:0003762 |
| obesity disorder | 3 | MONDO:0011122 | EFO:0001073 |
| chronic hepatitis C virus infection | 3 | MONDO:0005354 | EFO:0004220 |
| cutaneous melanoma | 3 | MONDO:0005012 | EFO:0000389 |
| metabolic dysfunction-associated steatotic liver disease | 3 | MONDO:0013209 | EFO:0003095 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| postmenopausal osteoporosis | 3 | MONDO:0008159 | EFO:0003854 |
| osteoporosis | 3 | MONDO:0005298 | EFO:0003882 |
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| femoral neck fracture | 3 | MONDO:0043589 | EFO:1001792 |
| burn | 3 | MONDO:0043519 | EFO:0009516 |
| pulmonary tuberculosis | 3 | MONDO:0006052 | EFO:1000049 |
| colonic neoplasm | 3 | MONDO:0005401 | EFO:0004288 |
| osteoarthritis, knee | 3 | MONDO:0005416 | EFO:0004616 |
| myocardial ischemia | 3 | MONDO:0024644 | EFO:1001375 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| Alzheimer disease | 3 | MONDO:0004975 | MONDO:0004975 |
| asthma | 3 | MONDO:0004979 | MONDO:0004979 |
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
| multiple sclerosis | 3 | MONDO:0005301 | MONDO:0005301 |
| tuberculosis | 3 | MONDO:0018076 | MONDO:0018076 |
| cardiovascular disorder | 3 | MONDO:0004995 | EFO:0000319 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| cluster headache syndrome | 3 | MONDO:0043537 | HP:0012199 |
| prostate adenocarcinoma | 2 | MONDO:0005082 | EFO:0000673 |
| Crohn disease | 2 | MONDO:0005011 | EFO:0000384 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| heart failure | 2 | MONDO:0005252 | EFO:0003144 |
| polycystic ovary syndrome | 2 | MONDO:0008487 | EFO:0000660 |
| restless legs syndrome | 2 | MONDO:0005391 | EFO:0004270 |
| optic neuritis | 2 | MONDO:0005885 | EFO:0007405 |
| cutaneous lupus erythematosus | 2 | MONDO:0005282 | EFO:0003834 |
| hepatitis C virus infection | 2 | MONDO:0005231 | EFO:0003047 |
| blood coagulation disease | 2 | MONDO:0001531 | EFO:0009314 |
| disseminated intravascular coagulation | 2 | MONDO:0001243 | HP:0005521 |
| endometrium neoplasm | 2 | MONDO:0021251 | MONDO:0011962 |
| diabetic neuropathy | 2 | MONDO:0006626 | EFO:1000783 |
| diabetes mellitus | 2 | MONDO:0005015 | EFO:0000400 |
| neuralgia | 2 | MONDO:0021667 | EFO:0005762 |
| migraine disorder | 2 | MONDO:0005277 | MONDO:0005277 |
| sickle cell disease | 2 | MONDO:0011382 | MONDO:0011382 |
| osteogenesis imperfecta | 2 | MONDO:0019019 | MONDO:0019019 |
| spinal cord injury | 2 | MONDO:0043797 | MONDO:0043797 |
| inflammatory bowel disease | 1 | MONDO:0005265 | EFO:0003767 |
| ulcerative colitis | 1 | MONDO:0005101 | EFO:0000729 |
| lung neoplasm | 1 | MONDO:0021117 | MONDO:0008903 |
| alopecia areata | 1 | MONDO:0005340 | EFO:0004192 |
| type 2 diabetes mellitus | 1 | MONDO:0005148 | MONDO:0005148 |
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
| infertility disorder | 1 | MONDO:0005047 | EFO:0000545 |
| colorectal neoplasm | 1 | MONDO:0005335 | MONDO:0005575 |
| mood disorder | 0 | MONDO:0005371 | EFO:0004247 |
| gestational diabetes | 0 | MONDO:0005406 | EFO:0004593 |
19 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 617.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 291 |
| PHASE4 | 110 |
| PHASE3 | 77 |
| PHASE2 | 71 |
| PHASE1 | 29 |
| EARLY_PHASE1 | 15 |
| PHASE2/PHASE3 | 13 |
| PHASE1/PHASE2 | 11 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02112734 | PHASE4 | ACTIVE_NOT_RECRUITING | Can Vitamin D Supplementation in the First Year of Life Prevent Food Allergy in Infants? The VITALITY Trial: Parts 1&2 |
| NCT03621553 | PHASE4 | RECRUITING | Vitamin D Homeostasis in Sarcoidosis |
| NCT05058976 | PHASE4 | ACTIVE_NOT_RECRUITING | Romosozumab Use to Build Skeletal Integrity |
| NCT07288801 | PHASE4 | RECRUITING | Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women |
| NCT00135304 | PHASE4 | COMPLETED | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism |
| NCT00160264 | PHASE4 | COMPLETED | Study to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal Women |
| NCT00271713 | PHASE4 | COMPLETED | Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D) |
| NCT00288873 | PHASE4 | COMPLETED | Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity |
| NCT00303485 | PHASE4 | COMPLETED | A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate) |
| NCT00424619 | PHASE4 | COMPLETED | A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients |
| NCT00497900 | PHASE4 | COMPLETED | The Effect of Calcium and Vitamin D in Patients With Heart Failure |
| NCT00581828 | PHASE4 | COMPLETED | Does Treatment of Hypovitaminosis D Increase Calcium Absorption? |
| NCT00668200 | PHASE4 | COMPLETED | Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget’s Disease Treated With Reclast® |
| NCT00803712 | PHASE4 | COMPLETED | 20070360 Incident Dialysis |
| NCT00846677 | PHASE4 | COMPLETED | Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips |
| NCT00869622 | PHASE4 | COMPLETED | Antiepileptic Drugs and Osteoporotic Prevention Trial |
| NCT00877123 | PHASE4 | COMPLETED | Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose |
| NCT00879970 | PHASE4 | TERMINATED | Thiazolidinedione Intervention With Vitamin D Evaluation |
| NCT00887354 | PHASE4 | COMPLETED | A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture |
| NCT00949832 | PHASE4 | COMPLETED | Vitamin D and Genetics in Nutritional Rickets |
| NCT00958451 | PHASE4 | COMPLETED | Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients |
| NCT01016184 | PHASE4 | COMPLETED | Influence of Vitamin D Treatment on Multi-systemic Functions in Young Men With Vitamin D Deficiency Due to Work Conditions |
| NCT01101698 | PHASE4 | UNKNOWN | Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients |
| NCT01112891 | PHASE4 | COMPLETED | Vitamin D in Pregnancy and Lactation |
| NCT01115842 | PHASE4 | UNKNOWN | Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI) |
| NCT01153243 | PHASE4 | UNKNOWN | Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes |
| NCT01187459 | PHASE4 | COMPLETED | Vitamin D in Pediatric Crohn’s Disease |
| NCT01199926 | PHASE4 | COMPLETED | Effect of Vitamin D Supplementation on Muscle Mass and Function |
| NCT01212406 | PHASE4 | COMPLETED | Vitamin D in Bronchiolitis Obliterans Syndrome |
| NCT01295879 | PHASE4 | COMPLETED | Vitamin D Repletion in Stone Formers With Hypercalciuria |
| NCT01306656 | PHASE4 | COMPLETED | Vitamin D Repletion in Primary Hyperparathyroidism |
| NCT01312441 | PHASE4 | TERMINATED | Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D |
| NCT01326650 | PHASE4 | COMPLETED | Vitamin D and Mortality in Heart Failure |
| NCT01395823 | PHASE4 | COMPLETED | Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients |
| NCT01400516 | PHASE4 | COMPLETED | Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial |
| NCT01416701 | PHASE4 | WITHDRAWN | Vitamin D and Chronic Obstructive Lung Disease |
| NCT01417923 | PHASE4 | UNKNOWN | The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain |
| NCT01437696 | PHASE4 | COMPLETED | How Much Vitamin D is Required to be Protective Against Deficiency During the Winter Months? |
| NCT01447173 | PHASE4 | COMPLETED | Vitamin and Asthma Study |
| NCT01518725 | PHASE4 | COMPLETED | The Effect of Vitamin D Supplementation on Muscle Power in Elite Cyclist |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: hypoparathyroidism, hypophosphatemic rickets, chronic kidney disease, breast neoplasm, hip fracture, vitamin D deficiency, obesity disorder, chronic hepatitis C virus infection, cutaneous melanoma, metabolic dysfunction-associated steatotic liver disease, leukemia, lymphoma, postmenopausal osteoporosis, osteoporosis, non-Hodgkin lymphoma, femoral neck fracture, burn, pulmonary tuberculosis, colonic neoplasm, osteoarthritis, knee, myocardial ischemia, severe acute respiratory syndrome, Alzheimer disease, asthma, type 1 diabetes mellitus, multiple sclerosis, tuberculosis, cardiovascular disorder, coronary artery disorder, cluster headache syndrome